Vantage 2019 Preview

Thumbnail
Thumbnail
Thumbnail

2019 expected to be volatile year for pharma and biotech industries

The Vantage 2019 Preview looks at the risks and opportunities for the year ahead.

Report Highlights

  • Venture capital and IPO markets are expected to retrench
  • The US FDA is expected to remain business friendly, but political gridlock may hinder pricing legislation
  • Alexion’s ALXN1210 is 2019’s most lucrative potential approval, with an NPV of $10.9bn

Following a sharp downturn in late 2018, the Pharma and Biotech sectors are entering 2019 in a state of uncertainty.

Investors are nervous, so are likely to become more cautious and selective in their choices. The potential upside of this could be a rallying M&A market as valuations drop, but data-led proof could be the key to attracting financing.

Expectations around immuno-oncology have been tempered due to some recent failures, however, cell and gene therapies remain popular with investors. 

Download Report

Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.